Edwards Lifesciences Buys Israeli MedTech Company Vectorious for USD 497M
Categories: Corporate and M&A
Edwards Lifesciences, a US-based global leader in heart valves and critical care monitoring, has acquired the remaining 48% stake in Israel’s Vectorious Medical Technologies, bringing the company’s valuation to USD 497 million. Edwards had already purchased a 52% stake in 2023 at a similar valuation.
Vectorious, headquartered in Israel, develops implantable monitoring devices for heart failure patients, advancing precision in cardiovascular care.
Fischer (FBC & Co.) advised Edwards Lifesciences on the acquisition, which gives Edwards full ownership of Vectorious, strengthening its portfolio of implantable cardiac solutions.
